ABT-737, 98%, a selective and BH3 mimetic Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively.

Name: ABT-737, 98%, a selective and BH3 mimetic Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. | 852808-04-9
Brand: J&K Chemical
SKU: JK831900_25_MG
Price: 248.0 USD
Availability: InStock

Cat. No JK831900_25_MG

Vendor: J&K Chemical

Product Information

Product Name

ABT-737, 98%, a selective and BH3 mimetic Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively.

Brand Name

J&K

Product Number

831900

CAS

852808-04-9

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

11228183

IUPAC Name

4-4-2-(4-chlorophenyl)phenylmethylpiperazin-1-yl-N-4-(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-ylamino-3-nitrophenylsulfonylbenzamide

InChI Key

HPLNQCPCUACXLM-PGUFJCEWSA-N

SMILES

CN(C)CCC@H(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)N+(=O)O-

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Exclusion of Notch from the contact site during efferocytosis restricts anticancer immunity

Publication Name: Nature Immunology

Publication Date: 2026-03-03

DOI: 10.1038/s41590-026-02452-3

HR-LCMS Guided Phytochemical Profiling and In vitro Anticancer Evaluation of Clematis heynei Fractions Against MCF-7 Cells using MTT Assay with Complementary In silico Docking Analysis

Publication Name: Chemistry Africa

Publication Date: 2026-03

DOI: 10.1007/s42250-025-01513-8

What does BCL-2 do? From new molecular insights to the clinical implications

Publication Name: Cell death and differentiation

Publication Date: 2026-02-19

DOI: 10.1038/s41418-025-01607-3

The second mitochondrial activator of caspases (SMAC) regulates growth, inflammation and mitochondrial integrity in cancer cells

Publication Name: Cell death and differentiation

Publication Date: 2026-02-03

DOI: 10.1038/s41418-026-01667-z

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome

Publication Name: Nature Aging

Publication Date: 2026-02-03

DOI: 10.1038/s43587-025-01054-2

ABT-737, 98%, a selective and BH3 mimetic Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively.

Product Information

General Information

Safety Information

References Data Source From Pubchem

Exclusion of Notch from the contact site during efferocytosis restricts anticancer immunity

HR-LCMS Guided Phytochemical Profiling and In vitro Anticancer Evaluation of Clematis heynei Fractions Against MCF-7 Cells using MTT Assay with Complementary In silico Docking Analysis

What does BCL-2 do? From new molecular insights to the clinical implications

The second mitochondrial activator of caspases (SMAC) regulates growth, inflammation and mitochondrial integrity in cancer cells

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome